A Phase 1/2 interventional study of UX-DA003 in Parkinson's Disease, sponsored by Shanghai UniXell Biotechnology Co., Ltd. Recruiting at 1 site in China. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Shanghai UniXell Biotechnology Co., Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.
Among the 279 studies in Parkinson Disease with a site in China, this one is the 174th largest by planned enrollment of the 211 interventional ones that give a count, is one of 41 that started in 2026, is one of 10 in phase 1/2, reaches primary completion later than 127 of the 134 other live ones, and was the 268th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Anhui Medical University · Sites in China
Ages 30–75
Hoffmann-La Roche · Sites in China, United States, Ireland and 2 more countries
Ages 40–85
Hangzhou PhecdaMed Co., Ltd. · Sites in China
Ages 18–80
Ruijin Hospital · Sites in China
Ages 50–85
Ke Dong, MD · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
279 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 28 · Phase 3 23 · Phase 4 11
First in 2003; this study’s year is marked. 41 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 47 across the 211 interventional studies, 215 across the 68 observational. Of the 97 that completed or were terminated, 19 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 279 have an industry lead sponsor. The 10 most frequent:
Shanghai UniXell Biotechnology Co., Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Shanghai UniXell Biotechnology Co., Ltd has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
41 of the studies in Parkinson Disease with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07725562Phase 3Zhejiang Vimgreen Pharmaceuticals, Ltd.VG081821AC Tablets for Early to Mid-stage Parkinson's Disease | 2027-10-01 |
| NCT07028632iRegene Therapeutics Co., Ltd.The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease | 2026-12 |
| NCT07604116Synusight Biotech (Shanghai) Co., Ltd.A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA | 2026-12 |
| NCT06642454Anhui Medical UniversityA Randomized Double-Blind Active-Controlled Crossover Trial of Respiratory-Gated Versus Non-Gated Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Motor and Non-Motor Symptoms in Parkinson's Disease | 2026-12-01 |
| NCT07384429YangPanEffects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease | 2026-12-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 279 studies in Parkinson Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical study is designed to explore the safety and tolerability of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.
This study is an open-label, multicenter, two-stage, Phase I/II clinical trial. Phase I study is a single-arm, open-label, dose-escalation clinical study aimed at evaluating the safety, tolerability, and preliminary efficacy of UX-DA003 transplantation therapy for PD patients across different dosage groups, as well as determining the recommended Phase II dose (RP2D). Eligible participants include PD patients who have experienced significant decline in response to standard anti-PD treatment and have not undergone DBS surgery. The study plans to establish two dosage. A total of 12 patients are planned for enrollment. Each patient will undergo a single dose of UX-DA003 for bilateral putamenal cell transplantation.
Phase II study is a single-arm, open-label, single-dose study aimed at further evaluating the efficacy and safety of UX-DA003 for the treatment of PD patients at the RP2D dose, providing evidence for Phase III confirmatory clinical studies. The enrollment population is the same as in the clinical Phase I. This phase includes only one dose group, with the dose being the recommended dose (RP2D) determined in the Phase I stage.
The trial visit schedule includes screening period (D-30\~D-8), baseline period (D-7\~D-1), surgery and postoperative observation period (D0\~D28), and follow-up period (M3\~M24).Patients who have completed the 24-month follow-up will enter the long-term follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: UX-DA003
UX-DA003 (Human Allogeneic iPSC-derived Midbrain Dopaminergic Progenitor cells) is used for treating patients with PD via implanting into bilateral putamina under stereotactic neurosurgery.
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Time frame: Within 6 months after administration
Changes in 18F-FP-CIT uptake detected by positron emission tomography (PET)
Time frame: Within 24 months after administration
Changes in MDS-UPDRS scores
Time frame: Within 24 months after administration
Changes in modified H&Y staging
Time frame: Within 24 months after administration
Changes in daily levodopa equivalent dose (LED)
Time frame: Within 24 months after administration
Changes in average daily 'off' and 'on' duration while awake
Time frame: Within 24 months after administration
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Aug 2029, 35 months after the start.
Of 55 phase 1/2 interventional studies under Parkinson Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 35 months is above that.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai UniXell Biotechnology Co., Ltd